SIRION Biotech participates in combined ABC of AAV offer at ESGCT 2019 Barcelona

Martinsried, Germany: – Viral technology specialist SIRION Biotech will be returning to the influential European Society for Gene and Cell Therapy (ESGCT) annual congress to present its ‘ABC of AAV’ offer.

SIRION has attended past ESGCT congresses and will be a prominent presence at the 2019 meeting, to be held in Barcelona as part of the ABC one-stop-shop adeno-associated virus (AAV) for Gene Therapy partnership also involving fellow German companies PROGEN, Genewerk and PlasmidFactory.

ABC of AAV combined experts

The combined ABC of AAV stand at Booths 19-22 at the Barcelona International Convention Center will display the consortium’s combined capabilities in adeno-associated virus engineering and production.

ABC of AAV services offers include safety evaluation, impurity detection, quantification, plasmid manufacture, ITR integrity, particle engineering and quantification, pre-clinical AAV production and GMP manufacturing services.

Advanced gene engineering

The SIRION team in Barcelona will be led by Managing Director and Chief Technology Officer Dr. Christian Thirion and Dr. Sabine Ott, Vice President for Licensing and Business Development.

They will also showcase its impressive portfolio of AAV advances, LentiBOOSTTM lentiviral transduction enhancer, lentiviral vector and adenovirus vector engineering and production capabilities.

“The annual ESGCT congress forms a wonderful platform for increasing our visibility, organizing partnering meetings, networking and getting updated with the latest trends,” commented Dr. Thirion.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION Biotech has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, cell and gene therapy and vaccination studies. It is SIRION’s mission to change the paradigm for viral vector supplies, with their ability to develop and supply all major viral vector types (adenovirus, lentivirus, AAV) within a matter of weeks at the concentration titers and quantities needed for preclinical human and animal testing.

Its unique focus on improving transduction efficiencies and safety makes SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOST™ transduction reagent is actively used to improve, among others, hematopoietic cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies. SIRION offerings include the transformational RNAiONE™ knockdown validation platform along with a full range of virus related services, ranging from particle production to virus driven cell modelling.

SIRION Biotech International is a wholly-owned subsidiary of SIRION Biotech GmbH providing custom engineering and manufacturing services of viral vectors for the life sciences industry.

About ESGCT 2019

The European Society of Gene and Cell Therapy (ESGCT) The European Society of Gene and Cell Therapy (ESGCT) promotes basic and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating education, the exchange of information and technology, and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.

The society’s annual congress provides an opportunity for scientists, clinicians and industry professionals to share new data, learn from peers, and discover global advances within the Gene and Cell Therapy field. The event currently attracts more than 1,000 delegates from some 40 countries worldwide.

The 20^th ESGCT / SETGYC Collaborative Congress (ESGCT 2019), is a four-day event opening October 22 at the Barcelona International Convention Center.

ESGCT 2019 is organised in collaboration with the Spanish Society for Gene and Cell Therapy SETGYC. Further information at: https://www.esgct.eu/Congress/Barcelona-2019.aspx